Twi Pharms Company Profile

What is the competitive landscape for TWI PHARMS, and when can generic versions of TWI PHARMS drugs launch?

TWI PHARMS has thirty-two approved drugs.

There is one US patent protecting TWI PHARMS drugs. There is one tentative approval on TWI PHARMS drugs.

There is one patent family member on TWI PHARMS drugs in one country and one hundred and thirty-three supplementary protection certificates in sixteen countries.

Summary for Twi Pharms

International Patents:	1
US Patents:	1
Tradenames:	29
Ingredients:	25
NDAs:	32

Drugs and US Patents for Twi Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Twi Pharms	ZESTRIL	lisinopril	TABLET;ORAL	019777-006	Jan 20, 1999	AB	RX	Yes	No
Twi Pharms	ATENOLOL	atenolol	TABLET;ORAL	072304-001	Jul 15, 1988	AB	RX	No	No
Twi Pharms	FLUPHENAZINE HYDROCHLORIDE	fluphenazine hydrochloride	TABLET;ORAL	215848-002	Apr 1, 2022	AB	RX	No	No
Twi Pharms	NIFEDIPINE	nifedipine	TABLET, EXTENDED RELEASE;ORAL	203126-001	Apr 3, 2014	AB2	RX	No	No
Twi Pharms	FLUPHENAZINE HYDROCHLORIDE	fluphenazine hydrochloride	TABLET;ORAL	215848-003	Apr 1, 2022	AB	RX	No	No
Twi Pharms	MEGESTROL ACETATE	megestrol acetate	SUSPENSION;ORAL	203139-001	Aug 27, 2014	AB	RX	No	No
Twi Pharms	DICLOFENAC SODIUM	diclofenac sodium	SOLUTION;TOPICAL	202393-001	Nov 24, 2014		DISCN	No	No

Expired US Patents for Twi Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Twi Pharms	TENORETIC 50	atenolol; chlorthalidone	TABLET;ORAL	018760-002	Jun 8, 1984	3,934,032
Twi Pharms	ZESTRIL	lisinopril	TABLET;ORAL	019777-001	May 19, 1988	4,374,829*PED
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-001	Approved Prior to Jan 1, 1982	3,934,032
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-003	Jan 5, 1996	5,637,320
Twi Pharms	TENORMIN	atenolol	TABLET;ORAL	018240-002	Approved Prior to Jan 1, 1982	3,934,032
Twi Pharms	TENORETIC 50	atenolol; chlorthalidone	TABLET;ORAL	018760-002	Jun 8, 1984	3,836,671
Twi Pharms	NAPRELAN	naproxen sodium	TABLET, EXTENDED RELEASE;ORAL	020353-001	Jan 5, 1996	5,637,320

Paragraph IV (Patent) Challenges for TWI PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	450 mg		2013-02-28

International Patents for Twi Pharms Drugs

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2008038155

Supplementary Protection Certificates for Twi Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	132014902277722	Italy		PRODUCT NAME: UNA COMBINAZIONE DI DAPAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE E METFORMINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE COME PROTETTI DAL BREVETTO DI BASE EP1506211(XIGDUO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/900, 20140116
2653873	23C1003	France		PRODUCT NAME: DIMETHYL FUMARATE; REGISTRATION NO/DATE: EU/1/13/837 20140203
1718641	2012/008	Ireland		PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
1261586	12C0028	France		PRODUCT NAME: ASSOCIATION COMPRENANT LA SAXAGLIPTINE OU UN DE SES SELS ET LA METFORMINE OU UN DE SES SELS, Y COMPRIS L'ASSOCIATION CHLORHYDRATE DE SAXAGLIPTINE ET CHLORHYDRATE DE METFORMINE; REGISTRATION NO/DATE: EU/1/11/731/001 20111124
1746976	LUC00026	Luxembourg		PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018
2316456	1790064-8	Sweden		PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330
0230742	2001C/040	Belgium		PRODUCT NAME: MONOHYDRATE DU CHLORHYDRATE DE N,N-DIMETHYL-1-4-CHLOROPHENYL)CYCLOBUTYL-3-METHYLBUTYLAMINE ET COMPOSITIONS PHARMACEUTIQUES LE CONTENANT; NAT. REGISTRTION NO/DATE: 479 IS 52 F 5 20010425; FIRST REGISTRATION: CH 54770 19990113

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Twi Pharms
• Twi Pharms Inc